Should Canadian patients look forward to aducanumab for Alzheimer disease?

Journal of Psychiatry Reform Vol 10 #12

This is an Open Access article from CMAJ distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence.

Open Access

Should Canadian patients look forward to aducanumab for Alzheimer disease?

Jennifer A. WattRoger MarpleBrenda Hemmelgarn and Sharon E. Straus

  • The recent approval of aducanumab by the US Food and Drug Administration was controversial.

  • Both phase 3 trials for aducanumab were terminated for futility after a prespecified interim analysis, and the clinical significance of their findings remains unclear.

  • Patients and clinicians are worried about aducanumab’s uncertain benefit, treatment burden (e.g., needing intravenous infusions of aducanumab every 4 weeks), safety and cost.

  • Currently, aducanumab is not approved for use in Canada, but it has been submitted to Health Canada for review.

In Canada, 190 000 people are living with mild Alzheimer-type dementia and 532 000 to 799 000 people are living with amnestic mild cognitive impairment.14 Developing treatments for Alzheimer disease is challenging, with few effective therapies that only target symptoms. Although the US Food and Drug Administration (FDA) approved aducanumab on June 7, 2021 — the first new treatment for Alzheimer disease since 2003 — its approval was controversial.5

Aducanumab is a human monoclonal immunoglobulin (Ig) G1 antibody that selectively targets amyloid-β aggregates (including soluble oligomers and insoluble fibrils) and clears amyloid plaques from the brain via a microglia-mediated phagocytic process. 6 Biogen sponsored ENGAGE (NCT02477800) and EMERGE (NCT02484547), which are both phase 3, parallel group, placebo-controlled randomized trials involving aducanumab. Both trials enrolled patients aged 50 to 85 years with mild cognitive impairment or mild dementia caused by Alzheimer disease who had a positron emission tomography (PET) scan that showed brain amyloid pathology. Patients were randomized to receive low-dose aducanumab, high-dose aducanumab or placebo for 18 months. Because of concern that carriers of apolipoprotein E (ApoE) episilon-4 could be at higher risk of developing amyloid-related imaging abnormalities (ARIA), than noncarriers, Biogen stratified patients by ApoE episolon-4 status.7 For example, ApoE epsilon-4 carriers who were randomized to high-dose aducanumab received 6 mg/kg and noncarriers received 10 mg/kg after a 24-week titration period.8However, the protocol was amended after a phase 1b randomized trial (completed after phase 3 trials began) established that it was safe to administer a 10 mg/kg dose to ApoE epsilon-4 carriers randomized to the high-dose aducanumab group.8

ENGAGE and EMERGE were both terminated for futility on Mar. 21, 2019, after a prespecified interim analysis, but Biogen successfully argued in support of aducanumab’s potential efficacy as a disease-modifying therapy based on posthoc analyses, and the FDA approved aducanumab for use in people with mild cognitive impairment or mild dementia caused by Alzheimer disease. 5,8 The FDA’s approval of aducanumab went against the recommendation of its independent Peripheral and Central Nervous System Drugs advisory committee, which recommended to the FDA that aducanumab not be approved because of lack of efficacy. Some trial analyses were conducted in close collaboration with the FDA, which may be perceived to have influenced the FDA’s decision.5,8

The FDA’s approval of aducanumab was also atypical because it was approved through the Accelerated Approval pathway, which is intended for drugs that are for a “serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.”5 Although aducanumab resulted in statistically significant time-and dose-dependent reductions in brain amyloid plaque compared with placebo, as measured by PET and other biomarkers in EMERGE and ENGAGE, the association between reduced amyloid levels and improvement in cognitive outcomes is uncertain.8,9 Furthermore, the accumulation of amyloid-β (i.e., the amyloid hypothesis) may not be the sole cause of Alzheimer disease, which makes its appropriateness as a surrogate end point questionable.8,9

Reliance on a surrogate end point, as opposed to primary and secondary clinical outcomes, was also important because of the uncertain clinical significance of clinical outcomes seen in the EMERGE trial. In the ENGAGE trial, neither statistically nor clinically significant treatment differences were found for primary or secondary clinical outcomes. For example, the minimum clinically important difference (i.e., the threshold above which clinicians, patients and researchers perceive a difference on an outcome scale) on the Clinical Dementia Rating-Sum of Boxes score (the primary outcome) is 1 to 2 points,10 but the difference in scores between high-dose aducanumab and placebo groups was −0.39 points (p = 0.0120) in EMERGE.8 Further, the minimum clinically important difference on the Mini-Mental State Examination is 1 to 3 points,10 but in the EMERGE trial, the difference between high-dose aducanumab and placebo groups in this secondary outcome was only 0.6 points (p = 0.0493).8

Patients in Canada living with mild cognitive impairment or mild dementia caused by Alzheimer disease hope for a drug that can provide them with clinically meaningful benefit, but it is unclear if aducanumab is this drug. They rightly worry about treatment burden (i.e., aducanumab is administered by intravenous infusion every 4 weeks and requires magnetic resonance imaging of the brain to monitor for ARIA) and potential adverse events.8 Pooled safety data from EMERGE and ENGAGE showed that, compared with the placebo group, the 10 mg/kg aducanumab group had higher rates of ARIA of edema or effusion (35.0% v. 2.7%), ARIA of microhemorrhages and hemosiderin deposits (20.5% v. 6.5%), headache (20% v. 15%) and falling (15% v. 12%); 10% of patients in the group receiving aducanumab at a dose of 10 mg/kg had symptomatic ARIA.8 Further, more patients in the aducanumab 10 mg/kg group stopped treatment because of an adverse event compared with placebo (8.8% v. 4.1%), which was secondary to an increased incidence of ARIA in the aducanumab group.8 This high incidence of ARIA was observed despite trial eligibility being limited to patients taking acetylsalicylic acid at a dose of 325 mg/d or less (i.e., excluding patients using other antiplatelet or anticoagulant agents) and potential healthy user bias, whereby clinical trial participants are healthier and therefore at lower risk of adverse outcomes than patients who will receive the drug in real-world settings. Patients also worry about potential treatment-related costs and whether aducanumab will be accessible to all patients for whom it is potentially indicated. In the United States, Biogen has priced aducanumab at $56 000 per year; however, the fair annual price is $2500 to $8300 per year.11

Results from the EMERGE and ENGAGE trials have not yet been published in a peer-reviewed journal. Biogen recently withdrew a manuscript from the Journal of the American Medical Association containing phase 3 clinical trial results for aducanumab. 12 Currently, aducanumab is not approved for use in Canada, but it has been submitted to Health Canada for review.13 Based on available data, as physicians and researchers (J.A.W., B.H., S.E.S.), we would not recommend its approval for use in Canada; R.M., a patient partner, will await Health Canada’s decision.


  • Competing interests: Roger Marple reports unpaid committee participation with AGE-WELL, the Alzheimer’s Society of Canada, the Alzheimer’s Society of Alberta and Northwest Territories, the World Health Organization and Dementia Advocacy Canada. No other competing interests were declared.

  • This article has been peer reviewed.

  • Contributors: All authors contributed to the manuscript’s conception and design. Jennifer Watt wrote the first manuscript draft. All authors provided feedback, approved the final manuscript version and agreed to be accountable for all aspects of this work.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See:


Print Friendly, PDF & Email